Skip to main content

Table 3 Correlations between changes in central biomarkers a

From: Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

 

Ventricular volume

CSF p-tau

CSF Aβ42

ADAScog11

MMSE

FDG-PET SUVR

−0.43; 0.007

−0.14; 0.79

0.37; 0.47

−0.11; 0.36

0.23; 08

Ventricular volume

1; 0

−0.14; 0.62

−0.12; 0.67

0.46; 0.001

−0.54; 0.001

CSF p-tau

 

1; 0

0.37; 0.49

−0.40; 0.02

0.33; 0.05

CSF Aβ42

  

1; 0

−0.12; 0.48

0.31; 0.08

ADAScog11

   

1; 0

−0.58; 0.001

  1. aAβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 11-item version; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio. Data are Spearman’s correlation coefficients and P-values (r; P).